Search research articles
Contact Us
Filters
Showing results (41-50 of 78) with videos related to
Page
of 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 11, 2014
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
K M Kerr, L Bubendorf, M J Edelman, et al.
British Journal of Cancer
|
December 9, 2003
Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations
R Stahel, A Rossi, L Petruzelka, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 1, 1997
Pretreatment minimal staging and prognostic factors for non-small cell lung cancer
R Feld, R Abratt, S Graziano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 1, 1995
Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK)
R A Joss, M Bacchi, C Hürny, et al.
British Journal of Cancer
|
July 2, 2014
Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing
S Patton, N Normanno, F Blackhall, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 2, 2008
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent
G Carteni, C Manegold, G Martin Garcia, et al.
Blood
|
May 1, 1997
CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells
S Aigner, Z M Sthoeger, M Fogel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2022
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data
M Pérol, E Felip, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 22, 2015
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
W E E Eberhardt, D De Ruysscher, W Weder, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 1, 1997
5th I.A.S.L.C. Lung Tumor Biology Workshop, August 13-17, 1996, Ermatingen, Switzerland
P Bunn, D Carbone, J Grim, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 78) with videos related to
Sort By:
Page
of 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 11, 2014
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
K M Kerr, L Bubendorf, M J Edelman, et al.
British Journal of Cancer
|
December 9, 2003
Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations
R Stahel, A Rossi, L Petruzelka, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 1, 1997
Pretreatment minimal staging and prognostic factors for non-small cell lung cancer
R Feld, R Abratt, S Graziano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 1, 1995
Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK)
R A Joss, M Bacchi, C Hürny, et al.
British Journal of Cancer
|
July 2, 2014
Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing
S Patton, N Normanno, F Blackhall, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 2, 2008
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent
G Carteni, C Manegold, G Martin Garcia, et al.
Blood
|
May 1, 1997
CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells
S Aigner, Z M Sthoeger, M Fogel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2022
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data
M Pérol, E Felip, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 22, 2015
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
W E E Eberhardt, D De Ruysscher, W Weder, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 1, 1997
5th I.A.S.L.C. Lung Tumor Biology Workshop, August 13-17, 1996, Ermatingen, Switzerland
P Bunn, D Carbone, J Grim, et al.
Page
of 8